Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 113

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 113
---
PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS (unaudited)

KEROS THERAPEUTICS, INC.

Condensed Consolidated Balance Sheets 

(In thousands, except share and per share data) 

(Unaudited)

MARCH 31,2025DECEMBER 31,2024ASSETSCURRENT ASSETS:Cash and cash equivalents$720,541 $559,931 Accounts receivable 17,291 2,742 Prepaid expenses and other current assets21,677 26,220 Total current assets759,509 588,893 Operating lease right-of-use assets18,667 19,251 Property and equipment, net4,473 4,237 Restricted cash1,449 1,449 Other long-term assets463 2,056 TOTAL ASSETS$784,561 $615,886 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:Accounts payable$6,636 $4,602 Current portion of operating lease liabilities2,102 1,978 Accrued expenses and other current liabilities17,290 20,870 Deferred revenue3,308 — Current tax liability10,043 — Total current liabilities39,379 27,450 Operating lease liabilities, net of current portion16,311 16,883 Total liabilities55,690 44,333 STOCKHOLDERS' EQUITY:Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding— — Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 40,562,047 and 40,554,705 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively4 4 Additional paid-in capital1,149,195 1,140,328 Accumulated deficit(420,328)(568,779)Total stockholders' equity728,871 571,553 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$784,561 $615,886 

See notes to condensed consolidated financial